Cervical Spondylosis Treatment Market Report 2025

The cervical spondylosis treatment market size has grown strongly in recent years. It will grow from $5.94 billion in 2024 to $6.32 billion in 2025 at a compound annual growth rate (CAGR) of 6.5%. The growth in the historic period can be attributed to aging population, increased prevalence of sedentary lifestyles, growth in awareness of cervical spondylosis, expansion of healthcare infrastructure, rise in musculoskeletal disorders.

The cervical spondylosis treatment market size is expected to see strong growth in the next few years. It will grow to $8.19 billion in 2029 at a compound annual growth rate (CAGR) of 6.7%. The growth in the forecast period can be attributed to growing healthcare investments, adoption of minimally invasive procedures, rise in patient awareness and education, increasing focus on preventive measures, integration of telemedicine in treatment approaches. Major trends in the forecast period include personalized treatment plans, rise of non-surgical interventions, development of home-based therapeutic solutions, integration of digital health platforms, emphasis on holistic and multidisciplinary approaches.

The rising prevalence of cervical spondylosis is anticipated to drive the growth of the cervical spondylosis treatment market in the future. Cervical spondylosis is a degenerative condition that impacts the joints and discs in the cervical spine (neck area). Treatments for this condition aim to alleviate pain, maintain individuals' activity levels, prevent irreversible damage to the spinal cord and nerves in those affected, and enhance overall well-being. For example, in May 2023, the National Institute of Health, a US-based government organization, stated that cervical spondylosis is considered a normal aspect of the aging process, affecting 95% of individuals by the age of 65. As a result, the growing prevalence of cervical spondylosis is fueling the demand for treatment options in this market.

The rise in healthcare expenditure is poised to fuel the expansion of the cervical spondylosis treatment market. Healthcare expenditure encompasses costs associated with providing health services, including aspects such as family planning, nutrition, and emergency medical assistance, with a primary focus on promoting health. Increased healthcare spending is instrumental in elevating patient awareness, facilitating early diagnosis, and enabling comprehensive management of cervical spondylosis. For instance, as outlined in the 2021-2030 National Health Expenditure (NHE) report published by the Centers for Medicare & Medicaid Services in March 2022, national health spending was projected to experience an average annual growth rate of 5.1% between 2021 and 2030, potentially reaching approximately $6.8 trillion by 2030. Consequently, the escalating healthcare expenditure serves as a significant driver propelling the cervical spondylosis treatment market.

Product innovations are a significant trend gaining traction in the cervical spondylosis treatment market. Leading companies in this sector are launching innovative products to maintain their market position. For example, in February 2024, NGMedical GmbH, a medical technology manufacturer based in Germany, introduced the MOVE-C artificial cervical disc in the United Arab Emirates, representing a noteworthy advancement in its global commercialization strategy. The first implantation of the MOVE-C disc took place in Abu Dhabi, showcasing the device's advanced design, which facilitates physiological movement and encourages bone ingrowth. This launch corresponds with the rising demand for innovative spinal treatments in the region, fueled by an increase in spinal disorders and population growth. Overall, the introduction of the MOVE-C is expected to improve patient outcomes and positively impact the artificial disc replacement market in the MENA region.

Prominent players in the market are strategically prioritizing the development of cutting-edge products, such as spinal support systems, to address the changing demands of patients and advancements in technology. Specifically, Aspen Medical Products, a US-based provider of solutions for pain and mobility management, unveiled the VRTX System in October 2023. This groundbreaking spine support system is meticulously crafted to offer comprehensive coverage from the cervical to sacrum regions. The VRTX System aims to revolutionize acute spinal care through its user-friendly prefabricated design and easily adjustable sizing, enabling healthcare professionals to promptly fit patients and stabilize their spines. This off-the-shelf solution is expected to reduce hospital stays, minimize complications, and enhance operational efficiency by optimizing time and inventory management. Featuring prefabricated components like CTO, TLSO, LSO, and CTLSO, each element within the VRTX System ensures optimal motion restriction and can be tailored to meet the specific needs of individual patients. This modular approach supports standardization of products and services within hospitals, promoting staff efficiency and elevating overall patient care.

In August 2023, ZimVie Inc., a US-based life sciences company operating in the dental and spine markets, announced an expansion of its collaboration agreement with Brainlab, a Germany-based leader in spine imaging, planning, and navigation solutions, incorporating robotic imaging, surgical assistance, and mixed reality technologies. This collaboration aims to merge ZimVie’s Vital and Virage fixation systems with Brainlab’s spine and trauma navigation technologies. By leveraging Brainlab's expertise, surgeons can effectively plan and execute spinal procedures, accurately position pedicle screws, and minimize radiation exposure, thereby enhancing the precision and safety of spinal surgeries.

Major companies operating in the cervical spondylosis treatment market include Johnson & Johnson, Merck & Co Inc., AbbVie Inc., GlaxoSmithKline Plc, Medtronic PLC, C.H. Boehringer Sohn AG & Co. KG, Amgen Inc., Stryker Corporation, B. Braun SE, Zimmer Biomet Holdings Inc., UCB Pharma S.A., Integra LifeSciences, NuVasive Inc., Globus Medical Inc., Orthofix Medical Inc., Aesculap Implant Systems LLC, Titan Spine Inc., Exactech Inc., SeaSpine Inc., RTI Surgical, Xtant Medical Holdings Inc., Zavation Medical Products LLC, Wenzel Spine Inc., Life Spine Inc., Spineology Inc., VGI Medical LLC, Dynamic Spine Inc., Synthes Holding AG, ZygoFix Ltd.

North America was the dominant region in the cervical spondylosis treatment market in 2024. The regions covered in the cervical spondylosis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cervical spondylosis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Cervical spondylosis treatment involves therapeutic interventions for a degenerative condition affecting the cervical spine (neck region) caused by wear and tear of spinal discs, joints, and bones. These treatments aim to alleviate pain, maintain individuals' activity levels, and prevent irreversible damage to the spinal cord and nerves.

The primary types of cervical spondylosis treatment include medications, physical therapy, and surgery. Medications are substances used for diagnosing, preventing, treating, or managing various medical conditions and diseases. In the context of cervical spondylosis treatment, medications are employed to reduce inflammation and alleviate symptoms associated with the condition. These treatments cater to both youth and the elderly and are administered in different settings, such as hospitals, ambulatory surgical centers, and homecare.

The cervical spondylosis treatment market research report is one of a series of new reports that provides cervical spondylosis treatment market statistics, including cervical spondylosis treatment industry global market size, regional shares, competitors with a cervical spondylosis treatment market share, detailed cervical spondylosis treatment market segments, market trends and opportunities, and any further data you may need to thrive in the cervical spondylosis treatment industry. This cervical spondylosis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The cervical spondylosis treatment market consists of revenues earned by entities by providing physical therapy services, neck traction services, diagnosis, consultation, and surgical services. The market value includes the value of related goods sold by the service provider or included within the service offering. The cervical spondylosis treatment market also includes the sales of nonsteroidal anti-inflammatory drugs, corticosteroids, and anti-seizure medications. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.